Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Learn how concave mirrors form images with a clear, step-by-step explanation that makes the mirror equation easy to ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF ...

There's more good news than bad news for this big biotech stock. Were Vertex's Q2 results horrible? Not at all. Instead, investors reacted negatively after the big biotech company announced two ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...